Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan

A Systematic Review and Meta-Analysis

Tania Jain, Fares Alahdab, Belal Firwana, Mohamad Bassam Sonbol, Diana Almader-Douglas, Jeanne Palmer

Research output: Contribution to journalArticle

Abstract

Fludarabine with busulfan (FB) or melphalan (FM) are 2 more commonly used reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (HCT).We present a systematic review and meta-analysis of studies comparing these 2 RIC regimens. We searched electronic databases from inception through November 1, 2017 for literature searches to identify relevant studies. A DerSimonian random effects model was used to measure efficacy outcomes; hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) are reported. Seven studies, including a total of 1955 patients, met criteria for inclusion, of which 6 were included in the overall pooled analysis because of repetition of some patients in 2 studies. Three studies were included in the subgroup analysis of acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS) and 2 in the subgroup analysis of lymphoid malignancies. Overall survival (OS) and progression-free survival were not statistically significantly different between the 2 RIC regimens in analysis of all studies. However, OS was better with FM in subgroup analysis of AML/MDS studies (HR,.83; 95% CI,.73 to.95). Nonrelapse mortality was lower with FB (HR,.64; 95% CI,.46 to.89), whereas relapse was lower with FM (HR, 1.52; 95% CI, 1.13 to 2.06) in the analysis of all studies. This meta-analysis shows that FB and FM are associated with a similar OS in patients undergoing HCT. Relapse rates are lower with FM but at the cost of higher nonrelapse mortality.

Original languageEnglish (US)
Pages (from-to)728-733
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume25
Issue number4
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Fingerprint

Busulfan
Melphalan
Stem Cell Transplantation
Meta-Analysis
Confidence Intervals
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Survival
Recurrence
Mortality
Disease-Free Survival
Outcome Assessment (Health Care)
fludarabine
Databases
Neoplasms

Keywords

  • Busulfan
  • Fludarabine
  • Melphalan
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan : A Systematic Review and Meta-Analysis. / Jain, Tania; Alahdab, Fares; Firwana, Belal; Sonbol, Mohamad Bassam; Almader-Douglas, Diana; Palmer, Jeanne.

In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 4, 01.04.2019, p. 728-733.

Research output: Contribution to journalArticle

@article{b4c2aac885174db2b11ff9024e56dacb,
title = "Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis",
abstract = "Fludarabine with busulfan (FB) or melphalan (FM) are 2 more commonly used reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (HCT).We present a systematic review and meta-analysis of studies comparing these 2 RIC regimens. We searched electronic databases from inception through November 1, 2017 for literature searches to identify relevant studies. A DerSimonian random effects model was used to measure efficacy outcomes; hazard ratios (HRs) and corresponding 95{\%} confidence intervals (CIs) are reported. Seven studies, including a total of 1955 patients, met criteria for inclusion, of which 6 were included in the overall pooled analysis because of repetition of some patients in 2 studies. Three studies were included in the subgroup analysis of acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS) and 2 in the subgroup analysis of lymphoid malignancies. Overall survival (OS) and progression-free survival were not statistically significantly different between the 2 RIC regimens in analysis of all studies. However, OS was better with FM in subgroup analysis of AML/MDS studies (HR,.83; 95{\%} CI,.73 to.95). Nonrelapse mortality was lower with FB (HR,.64; 95{\%} CI,.46 to.89), whereas relapse was lower with FM (HR, 1.52; 95{\%} CI, 1.13 to 2.06) in the analysis of all studies. This meta-analysis shows that FB and FM are associated with a similar OS in patients undergoing HCT. Relapse rates are lower with FM but at the cost of higher nonrelapse mortality.",
keywords = "Busulfan, Fludarabine, Melphalan, Reduced-intensity conditioning",
author = "Tania Jain and Fares Alahdab and Belal Firwana and Sonbol, {Mohamad Bassam} and Diana Almader-Douglas and Jeanne Palmer",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.bbmt.2018.11.016",
language = "English (US)",
volume = "25",
pages = "728--733",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan

T2 - A Systematic Review and Meta-Analysis

AU - Jain, Tania

AU - Alahdab, Fares

AU - Firwana, Belal

AU - Sonbol, Mohamad Bassam

AU - Almader-Douglas, Diana

AU - Palmer, Jeanne

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Fludarabine with busulfan (FB) or melphalan (FM) are 2 more commonly used reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (HCT).We present a systematic review and meta-analysis of studies comparing these 2 RIC regimens. We searched electronic databases from inception through November 1, 2017 for literature searches to identify relevant studies. A DerSimonian random effects model was used to measure efficacy outcomes; hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) are reported. Seven studies, including a total of 1955 patients, met criteria for inclusion, of which 6 were included in the overall pooled analysis because of repetition of some patients in 2 studies. Three studies were included in the subgroup analysis of acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS) and 2 in the subgroup analysis of lymphoid malignancies. Overall survival (OS) and progression-free survival were not statistically significantly different between the 2 RIC regimens in analysis of all studies. However, OS was better with FM in subgroup analysis of AML/MDS studies (HR,.83; 95% CI,.73 to.95). Nonrelapse mortality was lower with FB (HR,.64; 95% CI,.46 to.89), whereas relapse was lower with FM (HR, 1.52; 95% CI, 1.13 to 2.06) in the analysis of all studies. This meta-analysis shows that FB and FM are associated with a similar OS in patients undergoing HCT. Relapse rates are lower with FM but at the cost of higher nonrelapse mortality.

AB - Fludarabine with busulfan (FB) or melphalan (FM) are 2 more commonly used reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (HCT).We present a systematic review and meta-analysis of studies comparing these 2 RIC regimens. We searched electronic databases from inception through November 1, 2017 for literature searches to identify relevant studies. A DerSimonian random effects model was used to measure efficacy outcomes; hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) are reported. Seven studies, including a total of 1955 patients, met criteria for inclusion, of which 6 were included in the overall pooled analysis because of repetition of some patients in 2 studies. Three studies were included in the subgroup analysis of acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS) and 2 in the subgroup analysis of lymphoid malignancies. Overall survival (OS) and progression-free survival were not statistically significantly different between the 2 RIC regimens in analysis of all studies. However, OS was better with FM in subgroup analysis of AML/MDS studies (HR,.83; 95% CI,.73 to.95). Nonrelapse mortality was lower with FB (HR,.64; 95% CI,.46 to.89), whereas relapse was lower with FM (HR, 1.52; 95% CI, 1.13 to 2.06) in the analysis of all studies. This meta-analysis shows that FB and FM are associated with a similar OS in patients undergoing HCT. Relapse rates are lower with FM but at the cost of higher nonrelapse mortality.

KW - Busulfan

KW - Fludarabine

KW - Melphalan

KW - Reduced-intensity conditioning

UR - http://www.scopus.com/inward/record.url?scp=85059138011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059138011&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.11.016

DO - 10.1016/j.bbmt.2018.11.016

M3 - Article

VL - 25

SP - 728

EP - 733

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 4

ER -